Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion

Jeffrey M. Farma, James F. Pingpank, Steven K. Libutti, David L. Bartlett, Susan Ohl, Tatiana Beresneva, H. Richard Alexander

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Peritoneal carcinomatosis is a frequent mode of metastasis in patients with gastric, duodenal, or pancreatic cancer. Survival in this setting is short and therapeutic options are limited. This analysis examines the outcomes of 18 patients treated with operative cytoreduction and continuous hyperthermic peritoneal perfusion. Eighteen patients (6 males and 12 females) with gastric (n = 9), pancreatic (n = 7), or duodenal (n = 2) cancer were treated on protocol. Patients underwent optimal cytoreduction (complete gross resection, 11; minimal residual disease, 7) and a 90-minute perfusion with cisplatin. Clinical parameters and tumor and treatment characteristics were analyzed. Survival curves were estimated using the Kaplan-Meier method. Procedures included gastrectomy (n = 8), pancreaticoduodenectomy (n = 3), and hemicolectomy (n = 2). After cytoreduction, patients had no evidence of residual disease (n = 11), fewer than 100 implants less than 5 mm (n = 1), more than 100 implants between 5-10 mm (n = 3), or multiple implants with greater than 1 cm (n = 3). Five patients received a postoperative intraperitoneal dwell with 5-fluorouracil and paclitaxel. There was one perioperative mortality, and complications occurred in 10 patients. The median progression-free survival was 8 months (mean, 10 months; range, 1-47 months) with a median overall survival of 8 months (mean, 18 months; range, 1-74 months). In this cohort, peritoneal perfusion with cisplatin used to treat foregut malignancies has a high incidence of complications and does not significantly alter the natural history of the disease. Investigation of novel therapeutic approaches should be considered.

Original languageEnglish (US)
Pages (from-to)1346-1353
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume9
Issue number9
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Perfusion
Carcinoma
Survival
Neoplasms
Cisplatin
Duodenal Neoplasms
Pancreaticoduodenectomy
Residual Neoplasm
Gastrectomy
Paclitaxel
Pancreatic Neoplasms
Fluorouracil
Disease-Free Survival
Stomach Neoplasms
Stomach
Therapeutics
Neoplasm Metastasis
Mortality
Incidence

Keywords

  • Duodenal cancer
  • Gastric cancer
  • Pancreatic cancer
  • Peritoneal carcinomatosis
  • Peritoneal perfusion
  • Regional therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. / Farma, Jeffrey M.; Pingpank, James F.; Libutti, Steven K.; Bartlett, David L.; Ohl, Susan; Beresneva, Tatiana; Alexander, H. Richard.

In: Journal of Gastrointestinal Surgery, Vol. 9, No. 9, 01.12.2005, p. 1346-1353.

Research output: Contribution to journalArticle

Farma, Jeffrey M. ; Pingpank, James F. ; Libutti, Steven K. ; Bartlett, David L. ; Ohl, Susan ; Beresneva, Tatiana ; Alexander, H. Richard. / Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. In: Journal of Gastrointestinal Surgery. 2005 ; Vol. 9, No. 9. pp. 1346-1353.
@article{67313d6cd25642f1a249d53b358ff8f7,
title = "Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion",
abstract = "Peritoneal carcinomatosis is a frequent mode of metastasis in patients with gastric, duodenal, or pancreatic cancer. Survival in this setting is short and therapeutic options are limited. This analysis examines the outcomes of 18 patients treated with operative cytoreduction and continuous hyperthermic peritoneal perfusion. Eighteen patients (6 males and 12 females) with gastric (n = 9), pancreatic (n = 7), or duodenal (n = 2) cancer were treated on protocol. Patients underwent optimal cytoreduction (complete gross resection, 11; minimal residual disease, 7) and a 90-minute perfusion with cisplatin. Clinical parameters and tumor and treatment characteristics were analyzed. Survival curves were estimated using the Kaplan-Meier method. Procedures included gastrectomy (n = 8), pancreaticoduodenectomy (n = 3), and hemicolectomy (n = 2). After cytoreduction, patients had no evidence of residual disease (n = 11), fewer than 100 implants less than 5 mm (n = 1), more than 100 implants between 5-10 mm (n = 3), or multiple implants with greater than 1 cm (n = 3). Five patients received a postoperative intraperitoneal dwell with 5-fluorouracil and paclitaxel. There was one perioperative mortality, and complications occurred in 10 patients. The median progression-free survival was 8 months (mean, 10 months; range, 1-47 months) with a median overall survival of 8 months (mean, 18 months; range, 1-74 months). In this cohort, peritoneal perfusion with cisplatin used to treat foregut malignancies has a high incidence of complications and does not significantly alter the natural history of the disease. Investigation of novel therapeutic approaches should be considered.",
keywords = "Duodenal cancer, Gastric cancer, Pancreatic cancer, Peritoneal carcinomatosis, Peritoneal perfusion, Regional therapy",
author = "Farma, {Jeffrey M.} and Pingpank, {James F.} and Libutti, {Steven K.} and Bartlett, {David L.} and Susan Ohl and Tatiana Beresneva and Alexander, {H. Richard}",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.gassur.2005.06.016",
language = "English (US)",
volume = "9",
pages = "1346--1353",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion

AU - Farma, Jeffrey M.

AU - Pingpank, James F.

AU - Libutti, Steven K.

AU - Bartlett, David L.

AU - Ohl, Susan

AU - Beresneva, Tatiana

AU - Alexander, H. Richard

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Peritoneal carcinomatosis is a frequent mode of metastasis in patients with gastric, duodenal, or pancreatic cancer. Survival in this setting is short and therapeutic options are limited. This analysis examines the outcomes of 18 patients treated with operative cytoreduction and continuous hyperthermic peritoneal perfusion. Eighteen patients (6 males and 12 females) with gastric (n = 9), pancreatic (n = 7), or duodenal (n = 2) cancer were treated on protocol. Patients underwent optimal cytoreduction (complete gross resection, 11; minimal residual disease, 7) and a 90-minute perfusion with cisplatin. Clinical parameters and tumor and treatment characteristics were analyzed. Survival curves were estimated using the Kaplan-Meier method. Procedures included gastrectomy (n = 8), pancreaticoduodenectomy (n = 3), and hemicolectomy (n = 2). After cytoreduction, patients had no evidence of residual disease (n = 11), fewer than 100 implants less than 5 mm (n = 1), more than 100 implants between 5-10 mm (n = 3), or multiple implants with greater than 1 cm (n = 3). Five patients received a postoperative intraperitoneal dwell with 5-fluorouracil and paclitaxel. There was one perioperative mortality, and complications occurred in 10 patients. The median progression-free survival was 8 months (mean, 10 months; range, 1-47 months) with a median overall survival of 8 months (mean, 18 months; range, 1-74 months). In this cohort, peritoneal perfusion with cisplatin used to treat foregut malignancies has a high incidence of complications and does not significantly alter the natural history of the disease. Investigation of novel therapeutic approaches should be considered.

AB - Peritoneal carcinomatosis is a frequent mode of metastasis in patients with gastric, duodenal, or pancreatic cancer. Survival in this setting is short and therapeutic options are limited. This analysis examines the outcomes of 18 patients treated with operative cytoreduction and continuous hyperthermic peritoneal perfusion. Eighteen patients (6 males and 12 females) with gastric (n = 9), pancreatic (n = 7), or duodenal (n = 2) cancer were treated on protocol. Patients underwent optimal cytoreduction (complete gross resection, 11; minimal residual disease, 7) and a 90-minute perfusion with cisplatin. Clinical parameters and tumor and treatment characteristics were analyzed. Survival curves were estimated using the Kaplan-Meier method. Procedures included gastrectomy (n = 8), pancreaticoduodenectomy (n = 3), and hemicolectomy (n = 2). After cytoreduction, patients had no evidence of residual disease (n = 11), fewer than 100 implants less than 5 mm (n = 1), more than 100 implants between 5-10 mm (n = 3), or multiple implants with greater than 1 cm (n = 3). Five patients received a postoperative intraperitoneal dwell with 5-fluorouracil and paclitaxel. There was one perioperative mortality, and complications occurred in 10 patients. The median progression-free survival was 8 months (mean, 10 months; range, 1-47 months) with a median overall survival of 8 months (mean, 18 months; range, 1-74 months). In this cohort, peritoneal perfusion with cisplatin used to treat foregut malignancies has a high incidence of complications and does not significantly alter the natural history of the disease. Investigation of novel therapeutic approaches should be considered.

KW - Duodenal cancer

KW - Gastric cancer

KW - Pancreatic cancer

KW - Peritoneal carcinomatosis

KW - Peritoneal perfusion

KW - Regional therapy

UR - http://www.scopus.com/inward/record.url?scp=28644451665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644451665&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2005.06.016

DO - 10.1016/j.gassur.2005.06.016

M3 - Article

VL - 9

SP - 1346

EP - 1353

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 9

ER -